Lexeo Therapeutics (LXEO) has announced encouraging interim results for LX2006 in the treatment of Friedreich ataxia cardiomyopathy. The data revealed significant improvements in various cardiac biomarkers indicative of hypertrophy, a key characteristic of FA cardiomyopathy.
Eric Adler, Lexeo Therapeutics' Chief Medical Officer and Head of Research, remarked, "Given the positive safety profile and clinical advantages observed so far, we are eager to pursue rapid clinical development of LX2006, including the possibility of accelerated approval for this potentially life-saving therapy."
